Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Akebia Therapeutics (AKBA) Prepaid Assets (2016 - 2025)

Akebia Therapeutics (AKBA) has disclosed Prepaid Assets for 9 consecutive years, with $5.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Prepaid Assets changed N/A to $5.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $5.3 million, a N/A change, with the full-year FY2024 number at $11.4 million, up 97.25% from a year prior.
  • Prepaid Assets was $5.3 million for Q3 2025 at Akebia Therapeutics, down from $7.8 million in the prior quarter.
  • In the past five years, Prepaid Assets ranged from a high of $42.1 million in Q2 2022 to a low of $4.8 million in Q1 2024.
  • A 5-year average of $20.6 million and a median of $23.1 million in 2022 define the central range for Prepaid Assets.
  • Peak YoY movement for Prepaid Assets: soared 337.11% in 2021, then plummeted 82.49% in 2023.
  • Akebia Therapeutics' Prepaid Assets stood at $33.1 million in 2021, then decreased by 0.83% to $32.9 million in 2022, then tumbled by 82.49% to $5.8 million in 2023, then skyrocketed by 97.25% to $11.4 million in 2024, then crashed by 53.03% to $5.3 million in 2025.
  • Per Business Quant, the three most recent readings for AKBA's Prepaid Assets are $5.3 million (Q3 2025), $7.8 million (Q2 2025), and $11.4 million (Q4 2024).